arrow
S

Sagun Parakh

Austin Health
H指数:24
被引数:2,411

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment and Survival Outcomes for Indigenous and Non-Indigenous Australians Within the Victorian Lung Cancer Registry: A Retrospective Cross-Sectional Cohort Study

维多利亚肺癌登记处中土著和非土著澳大利亚人的治疗与生存结局:一项回顾性横断面队列研究

2026-07-290
OAAI
Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from the AURORA multi-centre registry (AURORA-ROS1)

ROS1重排非小细胞肺癌在演变的治疗时代中的真实世界治疗序列与生存情况:AURORA多中心登记研究(AURORA-ROS1)的结果

2026-06-170
PRE
A Bioimaging Study of 89Zr-Bintrafusp Alfa PET Scans in Patients with Advanced or Metastatic NSCLC Receiving Bintrafusp Alfa Alone or in Combination with Chemotherapy

89Zr-_bintrafusp alfa PET扫描的生物学成像研究:在单独接受bintrafusp alfa治疗或联合化疗的晚期或转移性非小细胞肺癌患者中的应用

2025-12-290
PRE
EP.17.02 Treatment and Survival Outcomes for Indigenous Australians Within the Victorian Lung Cancer Registry

EP.17.02 维多利亚肺癌登记系统中的原住民澳大利亚人治疗与生存结局

2025-10-230
PRE
Impact of Stage-Specific Guideline Concordant Treatment in Small Cell Lung Cancer in Victoria, Australia

澳大利亚维多利亚州小细胞肺癌中与分期特异性指南一致的规范治疗的影响

2025-09-110
OAAI
Impacts of a Clinical Quality Registry on Lung Cancer Quality Measures: A Retrospective Observational Study of the Victorian Lung Cancer Registry

临床肿瘤登记处对肺癌质量指标的影响:维多利亚肺癌登记处的回顾性观察研究

2025-05-260
OA
ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance

ALKTERNATE: 一项在ALK阳性NSCLC中交替使用氯拉替尼和克唑替尼的初步研究

2024-09-010
OA
First-in-human, phase I/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1/IDO1 antigen-specific therapy, in advanced/refractory solid tumors

首次人体研究,I/II期,单药治疗,剂量递增研究,针对mRNA-4359(一种mRNA编码的PD-L1/IDO1抗原特异性疗法)在晚期/难治性实体瘤中的应用

2024-09-014
PRE
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

奥希替尼和吉非替尼交替治疗晚期EGFR-T790M阳性非小细胞肺癌的II期试验: 振荡

2024-02-286
OAAI
A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases

IMpower150在癌基因驱动的肿瘤和CNS转移中的多中心真实世界经验

2022-12-014
PRE